Aprovel ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
167マルファン症候群2

167. マルファン症候群


臨床試験数 : 20 薬物数 : 39 - (DrugBank : 10) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-023612-14-GB
(EUCTR)
08/03/201320/12/2012The Oxford Marfan Trial A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 Marfan syndrome.
MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Aprovel
Product Name: Aprovel
INN or Proposed INN: Irbesartan
Trade Name: Vibrox 100mg Capsules
Product Name: Vibrox
INN or Proposed INN: Doxycycline Hyclate Ph.Eur
Clinical Trials and Research GovernanceNULLNot Recruiting Female: yes
Male: yes
56 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
2EUCTR2010-019302-16-GB
(EUCTR)
13/09/201017/08/2010A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndromeA prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome - The AIMS Study Marfan SyndromeTrade Name: Aprovel
Product Name: Aprovel
INN or Proposed INN: Irbesartan
INN or Proposed INN: Irbesartan
INN or Proposed INN: Irbesartan
Royal Brompton and Harefield NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
490 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited Kingdom